Supernus Pharmaceuticals (NASDAQ:SUPN) CEO Sells $779,920.74 in Stock

Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) CEO Jack Khattar sold 16,587 shares of the business’s stock in a transaction that occurred on Monday, September 22nd. The stock was sold at an average price of $47.02, for a total value of $779,920.74. Following the completion of the sale, the chief executive officer owned 1,122,456 shares of the company’s stock, valued at $52,777,881.12. The trade was a 1.46% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link.

Supernus Pharmaceuticals Price Performance

NASDAQ SUPN opened at $47.18 on Friday. Supernus Pharmaceuticals, Inc. has a 1 year low of $29.16 and a 1 year high of $47.65. The stock has a market capitalization of $2.65 billion, a PE ratio of 41.03 and a beta of 0.79. The business’s 50-day moving average is $41.74 and its 200 day moving average is $35.45.

Analysts Set New Price Targets

Several research firms recently commented on SUPN. Zacks Research upgraded Supernus Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a report on Wednesday, September 17th. Cantor Fitzgerald boosted their price target on Supernus Pharmaceuticals from $42.00 to $46.00 and gave the company an “overweight” rating in a report on Wednesday, August 6th. Piper Sandler raised their price objective on shares of Supernus Pharmaceuticals from $36.00 to $40.00 and gave the company a “neutral” rating in a research report on Friday, August 29th. Finally, Wall Street Zen upgraded Supernus Pharmaceuticals from a “hold” rating to a “buy” rating in a research note on Saturday, August 2nd. One investment analyst has rated the stock with a Strong Buy rating, two have given a Buy rating and one has assigned a Hold rating to the company. According to data from MarketBeat, Supernus Pharmaceuticals has an average rating of “Buy” and an average price target of $43.00.

Hedge Funds Weigh In On Supernus Pharmaceuticals

Large investors have recently bought and sold shares of the business. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its position in shares of Supernus Pharmaceuticals by 3.9% in the 4th quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 28,563 shares of the specialty pharmaceutical company’s stock valued at $1,033,000 after acquiring an additional 1,083 shares during the period. Two Sigma Advisers LP boosted its stake in shares of Supernus Pharmaceuticals by 14.7% in the fourth quarter. Two Sigma Advisers LP now owns 7,800 shares of the specialty pharmaceutical company’s stock worth $282,000 after acquiring an additional 1,000 shares during the last quarter. Principal Financial Group Inc. lifted its stake in shares of Supernus Pharmaceuticals by 3.2% in the first quarter. Principal Financial Group Inc. now owns 306,322 shares of the specialty pharmaceutical company’s stock worth $10,032,000 after buying an additional 9,590 shares in the last quarter. SG Americas Securities LLC raised its position in Supernus Pharmaceuticals by 63.6% in the first quarter. SG Americas Securities LLC now owns 17,671 shares of the specialty pharmaceutical company’s stock valued at $579,000 after purchasing an additional 6,867 shares during the period. Finally, Quantinno Capital Management LP lifted its position in Supernus Pharmaceuticals by 11.5% in the fourth quarter. Quantinno Capital Management LP now owns 8,401 shares of the specialty pharmaceutical company’s stock valued at $304,000 after buying an additional 864 shares during the last quarter.

Supernus Pharmaceuticals Company Profile

Supernus Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. The company's commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset seizures in adults and children between 6 to 17 years of age.